Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Abstract

This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET. Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq of 68Ga-IMP288, a histamine-succinyl-glycine peptide given after initial targeting of a trivalent anti-CEA, bispecific, antipeptide antibody. The gold standards were histology and imaging follow-up. Tumor SUVs (SUVmax and SUVmean) were measured, and tumor burden was analyzed using total tumor volume and total lesion activity. Results: The total lesion sensitivity of immuno-PET and 18F-FDG PET were 94.7% (1,116/1,178) and 89.6% (1,056/1,178), respectively. Immuno-PET had a somewhat higher sensitivity than CT or 18F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respectively) and liver metastases (97.3% vs. 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs. 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI or 18F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, respectively). In contrast to 18F-FDG PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and total tumor volume, total lesion activity was significantly higher with immuno-PET than with 18F-FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.

• Authors: Caroline Rousseau, David M Goldenberg, Mathilde Colombié, Jean-Charles Sébille, Philippe Meingan, Ludovic Ferrer, Pierre Baumgartner, Evelyne Cerato, Damien Masson, Mario Campone, Aurore Rauscher, Vincent Fleury, Catherine Labbe, Alain Faivre Chauvet, Jean-Sebastien Fresnel, Claire Toquet, Jacques Barbet, Robert M Sharkey, Loic Campion, Françoise Kraeber-Bodéré
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 61 Issue 8 Pg. 1205-1211 (08 2020) ISSN: 1535-5667 [Electronic] United States
• PMID: 32169921 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Chemical References

• Fluorodeoxyglucose F18
• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Adult
• Breast Neoplasms (diagnostic imaging, immunology, metabolism, therapy)
• Female
• Fluorodeoxyglucose F18
• Humans
• Middle Aged
• Positron-Emission Tomography
• Precision Medicine
• Prospective Studies
• Receptor, ErbB-2 (metabolism)